Surrozen, Inc.

NASDAQ•SRZN

CEO: Mr. Craig C. Parker M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-01-11

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

連絡先情報

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, 94080, United States

650-489-9000

www.surrozen.com

時価総額

$216.09M

PER (TTM)

-2.6

17.9

配当利回り

52週高値

$29.60

52週安値

$5.90

52週レンジ

81%

順位43Top 50.7%

3.8

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 3.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$983.00K-90.17%

直近4四半期の推移

EPS

-$8.36+1800.00%

直近4四半期の推移

フリーCF

-$9.06M+34.24%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Significant 2025 PIPE Funding Nine months financing provided 71.3M USD, primarily from the March 2025 PIPE proceeds, bolstering capital resources.

Related Party Revenue Surge Research service revenue reached 2.9M USD for nine months, driven by the TCGFB collaboration agreement executed in 2024.

Strong Cash Position Maintained Cash and equivalents totaled 81.3M USD as of September 30, 2025, supporting operations for at least 12 months.

SZN-8141 IND Filing Expected The company anticipates filing the Investigational New Drug application for SZN-8141 during 2026 to commence clinical studies.

リスク要因

Net Loss Widened Significantly Nine month net loss increased 66% to 58.9M USD in 2025, driven by higher R&D expenses and non-cash charges.

Operating Expenses Increased Total operating expenses rose 20% to 32.4M USD for nine months, primarily due to 29% growth in R&D spending.

TCGFB Collaboration Terminated Research Collaboration with TCGFB terminated effective November 2025, eliminating future related party revenue streams.

Future Capital Requirements High Expect continued losses and substantial additional capital needed to advance pipeline through clinical development and regulatory submissions.

見通し

Advance Key Ophthalmology Candidates Strategy focuses on advancing SZN-8141 and SZN-8143 through IND filing and into Phase 1 clinical studies in 2026.

Discontinued SZN-043 Development Development of SZN-043 halted in Q1 2025 due to insufficient early signal of clinical benefit for severe alcohol associated hepatitis.

2025 ATM Program Inactive The 50.0M USD At-the-Market program established in August 2025 has not yet resulted in any common stock sales as of period end.

Maintain Intellectual Property Rights Continued focus on securing and defending patent rights for Wnt platform and product candidates against potential third-party challenges.

同業比較

売上高 (TTM)

AGEN

$106.83M

-33.4%

ZNTL

$26.87M

-33.8%

MGX

$25.21M

-51.8%

粗利益率 (最新四半期)

SRZN

100.0%

+0.0pp

TCRX

71.8%

-30.5pp

ARMP

68.1%

-21.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ARMP	$383.73M	-8.2	70.3%	198.5%
GLSI	$370.47M	-18.6	-1042.8%	0.0%
IRD	$346.89M	-60.7	-452.3%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

14.5%

安定成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

25%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日

EPS:-$1.29

売上高:$661.00K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし